Neurogastrx Announces Positive Proof-of-Concept Data for Investigational Drug NG101 in Reducing Nausea and Vomiting Associated with the Administration of GLP-1 Agonist Medication
October 16, 2024 05:30 ET
|
Neurogastrx
Neurogastrx Announces Positive POC Data for Investigational Drug NG101 in Reducing Nausea & Vomiting Associated with GLP-1 Agonists
Neurogastrx Appoints Baxter Phillips III as President and Chief Executive Officer
November 03, 2015 11:50 ET
|
Neurogastrx
CAMPBELL, Calif., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Neurogastrx, a biopharmaceutical company engaged in developing novel drugs for gastrointestinal disorders, today announced the appointment of...